To further assess the safety profile of the fixed-dose combination of indacaterol and glycopyrronium ( QVA@ ) and its monocomponents ; we investigated the impact of individual patient-level factors and time by integrating the patient-level safety data from the QVA@ clinical programme with relevant information from the independent indacaterol and glycopyrronium safety databases .